high mobility group box 3Genealiases: HMG-2a · HMG-4 · HMG2A · HMG4
Q-omics provides the consensus-scored HMGB3 profile across patient tissues and cancer cell-line models. HMGB3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HMGB3 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, HMGB3 protein abundance shows 32,758 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where HMGB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB3 survival associations across molecular data types. HMGB3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB3 RNA expression–survival associations across cancer types. High HMGB3 expression shows unfavorable associations in ACC, UVM, KIRC, BRCA and SARC, but favorable associations in OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HMGB3 RNA expression.
This table summarizes HMGB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 13. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for HMGB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB3 shows higher tumor expression in HNSC, LUAD, BLCA, KIRP, LUSC and COAD. The HNSC box plot shows higher HMGB3 RNA expression in tumor versus normal tissue (log2 FC = +2.003, t-test p < 0.001).
This table shows molecular features associated with HMGB3 in patient tissues and cancer cell lines. In patient samples, HMGB3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HMGB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
